CN

You Are Leaving Avistone's Website

You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.

Cancel Continue
PRODUCT

PRODUCT

PRODUCT

It is the only MET inhibitor in China that has been approved for three indications (NSCLC and glioma)*, with two of the three included in China's 2024 National Reimbursement Drug List
Pharmacovigilance information

Vebreltinib Enteric Capsules(万比锐®)

It is the only MET inhibitor in China that has been approved for three indications (NSCLC and glioma)*, with two of the three included in China's 2024 National Reimbursement Drug List

[Indications]
  • NSCLC

    NSCLC

    Indication 1: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

    Indication 2: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) amplification.

  • Glioma

    Glioma

    Indication 3: Adult patients with IDH mutant astrocytoma (WHO grade 4) with the PTPRZ1-MET fusion who have experienced treatment failure in prior therapies or glioblastoma with LGG history.

*Till July of 2025

Pharmacovigilance information

Vebreltinib(万比锐®)

If you need to report adverse reactions occurring after using Vebreltinib, a product of Purun'ao, you can contact us through the following methods: 

 

Contact Phone: 010-84148592  (Weekdays 08:30-17:30, leave a message at other times)

Email: PV@pearlbio.cn

This information is for healthcare professionals' reference only. If you are a healthcare professional, please click 'Yes' to enter. If not, please click 'No'.

No Yes